Compounds > jm 2763
Page last updated: 2024-12-08

jm 2763

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

JM 2763: a bicyclam; structurally related to SID 791; inhibits human immunodeficiency replication [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID453871
CHEMBL ID28967
SCHEMBL ID599000
MeSH IDM0256879

Synonyms (12)

Synonym
1-[3-(1,4,8,11-tetrazacyclotetradec-1-yl)propyl]-1,4,8,11-tetrazacyclotetradecane
n,n'-bicyclampropane
1,4,8,11-tetraazatetradecane, 1,1'-(1,3-propanediyl)bis-
amd2763
n,n'-bis(1,4,8,11-tetra-azatetradecane)1,3-propane
110078-40-5
jm 2763
jm2763
1,3-di(1,4,8,11-tetraazacyclotetradecanyl)propane
CHEMBL28967
SCHEMBL599000
DTXSID10149136
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1288221Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay2016European journal of medicinal chemistry, May-23, Volume: 114Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
AID84657Cellular cytotoxicity against HUT-78 cells.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.
AID1288222Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells2016European journal of medicinal chemistry, May-23, Volume: 114Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
AID84661Antiretroviral activity against HIV-1 infected HUT-78 cells.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.
AID81801Inhibition of syncytium formation using HIV-1 IIIB strain gaint cell inhibition assay.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.
AID1383288Antiviral activity against HIV1 3B2018European journal of medicinal chemistry, Apr-10, Volume: 149The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.
AID84662Antiretroviral activity against HIV-2 infected HUT-78 cells.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		4.7350azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
krh 1636
KRH 1636: structure in first source		3.2710
amd 8664
[no description available]		4.1620
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		03.0410